Table 1.
Demographic and clinicopathological characteristics of poorly differentiated thyroid carcinoma.
| Patient number | n | Patient number | n |
|---|---|---|---|
| Median age (y) (min-max) | 57(8-85) | M0 | 71(75.5%) |
| Median year (y) (min-max) | 2017(2005-2020) | M1 | 23(24.5%) |
| Sex, n (%) | Surgery, n (%) | ||
| Male | 39(41.5%) | Biopsy or no surgery | 21(22.3%) |
| Female | 55(58.5%) | Thyroidectomy only | 44(46.8%) |
| Extrathyroidal extension, n(%) | Thyroidectomy +lymph node dissection | 29(30.9%) | |
| None | 11(11.7%) | Radiation, n (%) | |
| Yes | 83(88.3%) | None or refused | 45(47.9%) |
| Multifocality,n (%) | Radioactive iodine | 23(24.5%) | |
| None | 60(63.8%) | External beam radiotherapy | 26(27.7%) |
| Yes | 34(36.2%) | Chemotherapy, n (%) | |
| T stage (AJCC 8th), n (%) | None or unknown | 72(76.6%) | |
| T1 | 18(19.1%) | Yes | 22(23.4%) |
| T2 | 15(16.0%) | Associated thyroid cancer | |
| T3 | 7(7.4%) | Papillary only | 20(21.3%) |
| T4 | 54(57.4%) | Follicular only | 17(18.9%) |
| N stage (AJCC 8th), n (%) | Other | 34(36.2%) | |
| N0 | 16(17.0%) | None | 23(24.5%) |
| N1 | 78(83.0%) | Median recurrence-free survival time (m) (min-max) | 14(1-90) |
| M stage (AJCC 8th), n (%) | Median overall survival time (m) (min-max) | 33(1-170) |